Welcome to CureTech 


CureTech Ltd. is a biotechnology company developing novel, broad-spectrum, immune modulating products for the treatment and control of cancer. 

Building on the broad experience of its management, we have established a well-balanced portfolio of cancer therapies with our lead antibody, pidilizumab (CT-011), in late stage clinical testing. Our products are antibodies and peptide-based vaccines designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner.

Our Products

 

The company’s products are antibodies and peptide-therapeutics designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner.

Our lead product, pidilizumab (CT-011), is a humanized monoclonal antibody that exhibits efficient anti-cancer immune response against a wide variety of mouse and human tumor models. Pidilizumab is being developed as a treatment for hematological malignancies and solid tumors.